Compare · IMUX vs NVO
IMUX vs NVO
Side-by-side comparison of Immunic Inc. (IMUX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMUX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $180.22B, about 1548.2x IMUX ($116.4M).
- IMUX has been more active in the news (10 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 15 for IMUX).
- Company
- Immunic Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $116.4M
- $180.22B
- 1M return
- -
- +5.96%
- 1Y return
- -
- -14.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 10
- 9
- Recent ratings
- 15
- 25
Immunic Inc.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IMUX
- Amendment: SEC Form SCHEDULE 13G/A filed by Immunic Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Immunic Inc.
- SEC Form SCHEDULE 13G filed by Immunic Inc.
- Immunic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Immunic Inc.
- Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Immunic Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Immunic Inc.
- Immunic to Participate in Investor Conferences in November
- Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S